NCT06989112
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06989112
Title DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01)
Acronym DE-01
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | SWE | POL | NOR | NLD | ITA | HUN | GBR | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS